Lastly, to investigate whether TIGIT ± PD-L1 blockade could add value in the context of adoptive cell therapies, we analyzed single-cell RNA sequencing data from a recent clinical trial with anti-GD2 CAR-NKT cells in neuroblastoma. The gene discussed is CD274; the disease is neuroblastoma.